Zai Lab reports phase 1b trial data for lung cancer treatment

Zai Lab reported that zoci 1.6 mg/kg plus atezolizumab showed an 81.8% ORR and 81.9% 6-month PFS rate in first-line ES-SCLC. Grade >3 AEs related to zoci were 9.1%. A Phase 3 study is planned to start by year-end 2026, according to the company.

Zai Lab's (ZLAB) drug zocilurtatug pelitecan (zoci) showed 81.8% response rate and 81.9% 6-month progression-free survival in a Phase 1b trial for extensive-stage small cell lung cancer. The combination with atezolizumab was well-tolerated. A Phase 3 trial is planned for 2026. Zai Lab will discuss the data in an investor call.

Zai Lab reported Phase 1b data for zocilurtatug pelitecan in first-line ES-SCLC, showing high response rates and tolerability. The company plans to start a global Phase 3 study. According to the company, the data supports a platinum-free regimen with atezolizumab.

Zai Lab's drug combo, zoci plus atezolizumab, showed an 81.8% response rate and 81.9% 6-month progression-free survival in extensive-stage small-cell lung cancer (ES-SCLC) patients. 66.7% of 15 patients had no progression or death after six months. The treatment was well-tolerated, with Grade 3+ adverse events in 9.1% of patients. Zai Lab plans to initiate a global Phase 3 trial by year-end 2026.

Zai Lab (ZLAB) raised $250 million by selling 11.34 million ADSs at $22.04 each to accredited investors. The company plans to use the proceeds for pipeline development, working capital, and general corporate purposes. The transaction is expected to close on or about October 27, 2026, with a registration rights agreement filed within 15 days after closing.

Zai Lab (ZLAB) will sell 11.34M ADSs at $22.04 each in a PIPE deal, raising $250M before fees. The company plans to use proceeds for general corporate purposes and strategic initiatives, according to the agreement.